Integrated Fundamentals

INBP -  USA Stock  

USD 1.08  0.01  0.92%

Integrated Biopharma fundamentals help investors to digest information that contributes to Integrated Biopharma's financial success or failures. It also enables traders to predict the movement of Integrated OTC Stock. This fundamental analysis module provides a way for investors to measures Integrated Biopharma's intrinsic value by examining all of its available economic and financial indicators and drivers, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Integrated Biopharma otc stock. Please note, this module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Integrated Fundamentals 

Integrated Biopharma Selling General and Administrative Expense is very stable at the moment as compared to the past year. Integrated Biopharma reported last year Selling General and Administrative Expense of 3.7 Million. As of 25th of October 2021, Weighted Average Shares is likely to grow to about 29.9 M, while Operating Income is likely to drop about 4.7 M.

Integrated Price to Sales Analysis

Integrated Biopharma's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
 2018 2019 2020 2021 (projected)
Cost of Revenue43.76 M46.04 M54.08 M52.67 M
Consolidated Income1.69 M4.11 M8.01 M8.65 M
MV Per Share 
Revenue Per Share 
More About Price to Sales | All Equity Analysis

Current Integrated Biopharma Price to Sales

  0.54 X  
Most of Integrated Biopharma's fundamental indicators, such as Price to Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Integrated Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Integrated Price to Sales Historical Pattern

Today, most investors in Integrated Biopharma OTC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Integrated Biopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Integrated Biopharma price to sales as a starting point in their analysis.
 Integrated Biopharma Price to Sales 
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Compare to competition

Integrated Price to Sales Ratio

Price to Sales Ratio

Integrated Biopharma Price to Sales Ratio is very stable at the moment as compared to the past year. Integrated Biopharma reported last year Price to Sales Ratio of 0.51
Based on the latest financial disclosure, the price to sales indicator of Integrated Biopharma is roughly 0.54 times. This is 77.78% lower than that of the Consumer Defensive sector and 95.34% lower than that of the Packaged Foods industry. The price to sales for all United States stocks is 95.27% higher than that of the company.

Integrated Biopharma Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Integrated Biopharma's current stock value. Our valuation model uses many indicators to compare Integrated Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Integrated Biopharma competition to find correlations between indicators driving Integrated Biopharma's intrinsic value. More Info.
Integrated Biopharma is currently regarded as number one stock in current liabilities category among related companies. It is currently regarded as number one stock in book value per share category among related companies . The ratio of Current Liabilities to Book Value Per Share for Integrated Biopharma is about  35,730,303 . Integrated Biopharma Current Liabilities is very stable at the moment as compared to the past year. Integrated Biopharma reported last year Current Liabilities of 9.24 Million. Comparative valuation analysis is a catch-all model that can be used if you cannot value Integrated Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Integrated Biopharma's OTC Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Integrated Biopharma's earnings, one of the primary drivers of an investment's value.

Integrated Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Integrated Biopharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Integrated Biopharma could also be used in its relative valuation, which is a method of valuing Integrated Biopharma by comparing valuation metrics of similar companies.
Integrated Biopharma is currently under evaluation in current valuation category among related companies.

Integrated Biopharma Current Valuation Drivers

We derive many important indicators used in calculating different scores of Integrated Biopharma from analyzing Integrated Biopharma's financial statements. These drivers represent accounts that assess Integrated Biopharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Integrated Biopharma's important valuation drivers and their relationship over time.
201620172018201920202021 (projected)
Average Assets14.61 M14.55 M21.08 M20.8 M25.37 M23.96 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA3.16 M2.28 M3.45 M4.26 M8.33 M8.99 M
Earnings Before Interest Taxes and Depreciation Amortization USD3.16 M2.28 M3.45 M4.26 M8.33 M8.99 M
Earnings before Tax1.86 M1 M2.04 M3.09 M7.25 M7.82 M
Average Equity(7.2 M)(5.96 M)985.75 K3.91 M9.91 M10.69 M
Enterprise Value18.4 M17.26 M16.52 M21.91 M40.83 M34.28 M
Free Cash Flow70 K927 K(86 K)1.13 M2.75 M2.97 M
Invested Capital19.17 M12.72 M19.86 M20.58 M21.99 M21.9 M
Invested Capital Average18.29 M16.28 M17.58 M18.53 M20.21 M20.89 M
Market Capitalization4.01 M3.17 M6.8 M13.3 M32.75 M35.33 M
Tangible Asset Value15.2 M14.57 M19.79 M22.94 M25.44 M23.54 M
Working Capital1.4 M(3.92 M)1.73 M3.36 M8.76 M9.45 M

Integrated Fundamentals

About Integrated Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Integrated Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Integrated Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Integrated Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2021
Cost of Revenue54.1 M52.7 M
Revenues63.6 M61.3 M
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Integrated Biopharma operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 143 people.

Integrated Biopharma Investors Sentiment

The influence of Integrated Biopharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Integrated. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - INBP

Integrated Biopharma Investor Sentiment

Most of Macroaxis users are currently bullish on Integrated Biopharma. What is your judgment towards investing in Integrated Biopharma? Are you bullish or bearish?
98% Bullish
2% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Integrated Biopharma using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Integrated Biopharma Piotroski F Score and Integrated Biopharma Altman Z Score analysis. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Integrated OTC Stock analysis

When running Integrated Biopharma price analysis, check to measure Integrated Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Biopharma is operating at the current time. Most of Integrated Biopharma's value examination focuses on studying past and present price action to predict the probability of Integrated Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Integrated Biopharma's price. Additionally, you may evaluate how the addition of Integrated Biopharma to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
CEO Directory
Screen CEOs from public companies around the world
Transaction History
View history of all your transactions and understand their impact on performance
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Money Managers
Screen money managers from public funds and ETFs managed around the world
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Is Integrated Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Integrated Biopharma. If investors know Integrated will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Integrated Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Integrated Biopharma is measured differently than its book value, which is the value of Integrated that is recorded on the company's balance sheet. Investors also form their own opinion of Integrated Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Integrated Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Integrated Biopharma's market value can be influenced by many factors that don't directly affect Integrated Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Integrated Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Integrated Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Integrated Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.